(function(){var loadHandler=window['sl_{07577339-214E-45D2-8349-B551DFC3D55F}'];loadHandler&&loadHandler(30, '<div id="spr0_5382c1e"><div id="spr1_5382c1e" class="kern"><img id="img2_5382c1e" src="data/img5.png" width="960px" height="540px" alt="" style="left:0px;top:0px;"/><div id="spr3_5382c1e" style="left:-3px;top:71px;"><img id="img0_5382c1e" src="data/img6.png" width="968" height="120" alt=""/></div><div id="spr4_5382c1e" style="left:0px;top:-0.625px;"><img id="img1_5382c1e" src="data/img7.png" width="961" height="156.326" alt=""/></div></div><div id="spr2_5382c1e" class="kern"><div id="spr5_5382c1e" style="left:48px;top:21.625px;"><div style="width:0px;"><span id="txt0_5382c1e" class="relpos" style="left:103.728px;top:11.383px;">What are the new findings?</span></div></div><div id="spr6_5382c1e" style="left:48px;top:133.922px;"><div style="width:0px;"><span id="txt1_5382c1e" class="nokern relpos" style="left:7.2px;top:4.724px;">•</span><span id="txt2_5382c1e" class="relpos" style="left:25.798px;top:4.835px;">Mutations </span><span id="txt3_5382c1e" class="relpos" style="left:25.793px;top:4.835px;">in </span><span id="txt4_5382c1e" class="relpos" style="left:25.788px;top:4.835px;">KRAS</span><span id="txt5_5382c1e" class="relpos" style="left:25.783px;top:4.835px;"> and/or </span><span id="txt6_5382c1e" class="relpos" style="left:25.778px;top:4.835px;">GNAS </span><span id="txt7_5382c1e" class="relpos" style="left:25.773px;top:4.835px;">by next-generation sequencing</span></div><div style="width:0px;"><span id="txt8_5382c1e" class="relpos" style="left:34.2px;top:33.635px;">(NGS) are </span><span id="txt9_5382c1e" class="relpos" style="left:34.195px;top:33.635px;">highly sensitive and specific for intraductal papillary</span></div><div style="width:0px;"><span id="txt10_5382c1e" class="relpos" style="left:34.2px;top:62.435px;">mucinous neoplasms (IPMNs)</span><span id="txt11_5382c1e" class="relpos" style="left:34.195px;top:62.435px;">, </span><span id="txt12_5382c1e" class="relpos" style="left:34.19px;top:62.435px;">but not mucinous cystic neoplasms</span></div><div style="width:0px;"><span id="txt13_5382c1e" class="relpos" style="left:34.2px;top:91.235px;">(MCNs).</span></div><div style="width:0px;"><span id="txt14_5382c1e" class="nokern relpos" style="left:7.2px;top:125.684px;">•</span><span id="txt15_5382c1e" class="relpos" style="left:25.798px;top:125.795px;">The sensitivity of preoperative DNA-based testing for IPMNs and MCNs was</span></div><div style="width:0px;"><span id="txt16_5382c1e" class="relpos" style="left:34.2px;top:154.595px;">lower with Sanger sequencing than NGS.</span></div><div style="width:0px;"><span id="txt17_5382c1e" class="nokern relpos" style="left:7.2px;top:189.044px;">•</span><span id="txt18_5382c1e" class="relpos" style="left:25.798px;top:189.155px;">The preoperative detection of mutations/deletions in </span><span id="txt19_5382c1e" class="relpos" style="left:25.793px;top:189.155px;">TP53, PIK3CA</span></div><div style="width:0px;"><span id="txt20_5382c1e" class="relpos" style="left:34.2px;top:217.955px;">and/or PTEN with mutant allele frequencies (MAFs) </span><span id="txt21_5382c1e" class="relpos" style="left:34.195px;top:217.955px;">that are</span></div><div style="width:0px;"><span id="txt22_5382c1e" class="relpos" style="left:34.2px;top:246.755px;">equivalent to MAFs for KRAS and/or GNAS mutations was </span><span id="txt23_5382c1e" class="relpos" style="left:34.195px;top:246.755px;">highly sensitive</span></div><div style="width:0px;"><span id="txt24_5382c1e" class="relpos" style="left:34.2px;top:275.555px;">and specific for IPMNs with advanced neoplasia (high-grade dysplasia and</span></div><div style="width:0px;"><span id="txt25_5382c1e" class="relpos" style="left:34.2px;top:304.355px;">invasive adenocarcinoma).</span></div></div><div id="spr7_5382c1e" style="left:786.204px;top:511.855px;"><div style="width:0px;"><span id="txt26_5382c1e" class="relpos" style="left:8.85px;top:4.31px;">Gut 2018;676:2131-2141</span></div></div></div></div>');})();